Coalition to Save Pure Files Proxy Documents With SEC, Urges Pure's Board to Set an Annual Meeting Date

The Coalition to Save Pure, a group of stockholders and director nominees that has nominated a slate of six individuals to replace the current board of directors of Pure Bioscience, Inc.

, today filed its preliminary proxy statement with the Securities and Exchange Commission. Pure owns the rights to silver dihydrogen citrate (SDC), an antibacterial, antiviral and antifungal technology.